agilon health (AGL) investor relations material

Business transformation and strategy

• Shifted focus from rapid growth to profitability over the past 18 months, doubling company size in 2024 and executing disciplined operating strategies.

• Enhanced data visibility, clinical outcomes, and technology-enabled scalability, including AI-driven analytics.

• Rolled out mature clinical programs, notably heart failure, across 90% of the network, with new programs in COPD and dementia underway.

• Reduced operating expenses by $35 million, directly benefiting the bottom line.

• Transformation efforts are now reflected in improved earnings for the first and second quarters.

Financial performance and guidance

• EBITDA guidance for 2026 raised to $75–$95 million, driven by disciplined contracting, quality incentives, and risk carve-outs.

• Achieved a 3% net risk adjustment lift, up from initial 40 basis points, due to clinical program success and improved data models.

• Cost trend outperformed expectations, with Q1 restated to low 6% and prudent 7% guidance for the remainder of the year.

• Each 1% change in medical cost trend equates to $50 million in medical margin and $25 million in EBITDA.

• Cash balance at quarter-end was $257 million (excluding ACO entities), with expectations to end the year with at least $125 million.

Data and operational improvements

• 85% of payer partners now on an enhanced data pipeline, enabling real-time revenue and cost estimation and improved risk adjustment accuracy.

• Redesigned reserving and estimation processes for both revenue and medical costs, leveraging member-level risk scores.

• Data delays persist, but ongoing efforts aim to reduce lag and further improve estimation accuracy.

• Conservative financial positioning adopted due to past challenges, now supported by robust data reconciliation.